Pfizer is very interested in the sublingual Viagra!
Teuto and Pfizer close unpublished partnership
A great partnership was announced last Wednesday, October 21st, in Sao Paulo. Pfizer the American company and Laboratorio Teuto Brasileiro S/A announced a partnership where the multinational now holds 40% of the Brazilian industry. The focus of such deal is the generic medicine production.
The deal had a worldwide repercussion and it valued the value of Pfizer´s shares in the New York´s Stock market. In the economy editorials of the Brazilian newspapers the issue was the entrance of Pfizer into the generic medicine Brazilian market. Laboratorio Teuto, pioneer in the generic production in Brazil, occupies the third place (in units) in the ranking of pharmaceutical companies that produce generics in the country.
The deal was closed with R$400 million reais and it may represent a much larger figure considering the technological advances and the benefits on the population that may come up with this partnership. At first Teuto will be able to distribute Pfizer´s medicines in its sales points and vice versa.
The agreement will also allow a second instance where Teuto will launch its generic medicine as well as Pfizer generics, and the American company will be able to produce Teuto´s products. The partnership between both companies is also an alignment commercially speaking, since Laboratorio Teuto serves more than 36 thousand independent pharmacies and Pfizer has a great commercial partnership with the largest networks and also within the largest centers.
Present in Brazil for over 60 years, Pfizer closed such partnership with Teuto for being a company of great potential in Brazil, Teuto which has a solid history and continuous growth. Moreover, the company has an excellent industrial park, operation, distribution network, quality and portfolio, composed by generic medicine, prescription exempted (OTCs) and similars, with more than 400 presentations.
“For Teuto such partnership with Pfizer is of great importance for our business objectives. We will expand our product portfolio to meet the patients and market demands,” Marcelo Henriques comments, Teuto President. The partnership also means development for the State of Goias with more business opportunities and Jobs.
Teuto Generics – Nowadays Teuto has the main active principles (API) commercialized and it is one of the sales championships in the pharmacies from all over the country. It has been establishing as one of the main players within such market. Laboratorio Teuto invests 7% of its revenue on Research and Development with the objective of strengthening even more the generic line and new drugs, it also has partnerships with universities and research centers all over the world t offer an updated and aligned portfolio with the market needs.
Laboratorio Teuto´s forecast is that over the upcoming years, with the product patent fall there will be a great volume sale, this market may gain muscle, increasing substantially its share in the market, reaching a total of 35% of the pharmaceutical medicine overall. Such increase is defined by ANIVISA (National Agency of Sanitary Surveillance). According to Dirceu Raposo, ANVISA President, it is necessary a larger disclosure coming from the laboratories themselves and that doctors and hospitals guide the patients about any of both medicines, generic or reference, since both can meet the treatment needs.
